The NanoBiotechnology Group is mainly focused on the use of bioactive molecules and nanoparticles in nanomedicine & nanotechnology. It possesses a multidisciplinary philosophy, combining the expertise of Dr. Alvaro Somoza, an expert in the use of modified oligonucleotides and nanostructures in nanomedicine, and Dr. Begoña Sot, an expert in protein engineering. The group deals with several research lines, centered on the use of modified oligonucleotides and proteins to create new nanomedical tools and sensors. Specifically, the current research topics are:
- Nanoparticles in Drug Delivery, using different nanostructures to deliver different drugs and nucleic acids for the treatment of different diseases.
- Design of new immunotherapy tools based in engineered molecular chaperones and gold nanoparti- cles able to load Antigen Presenting Cells with antigens and siRNAs for their use in immunotherapy.
- The design of new strategies for an efficient editing of Uveal Melanoma and Pancreatic cancer cell lines based on Cas proteins.
- Nanosensors for multiples diseases, such as Uveal, Melanoma, Pancreatic cancer or Duchenne Muscular Dystrophy.